metastatic renal cell carcinomatargeted therapyVHL gene mutationpromoter hypermethylationметастатический рак почкитаргетная терапиямутации гена VHLгиперметилирование промотора1.1. Михайленко Д.С., Григорьева М.В., Землякова В.В. и др. Молекулярногенетические нарушения в гене VHL и метилирование некоторых генов супрессоров в спорадических светлоклеточных карциномах почки. Онкоурология 2010;(2):32−6.Михайленко Д.С., Григорьева М.В., Землякова В.В. и др. Молекулярногенетические нарушения в гене VHL и метилирование некоторых генов супрессоров в спорадических светлоклеточных карциномах почки. Онкоурология 2010;(2):32−6.2.2. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 1997;80:1198−220.Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 1997;80:1198−220.3.3. Lonser R.R., Glenn G.M., Walther M. et al. Von Hippel-Lindau disease. Lancet 2003;361:2059–67.Lonser R.R., Glenn G.M., Walther M. et al. Von Hippel-Lindau disease. Lancet 2003;361:2059–67.4.4. Latif F., Tory K., Gnarra J. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317–20.Latif F., Tory K., Gnarra J. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317–20.5.5. Iliopoulos O., Levy A.P., Jiang C. et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595–9.Iliopoulos O., Levy A.P., Jiang C. et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595–9.6.6. Foster K., Prowse A., van den Berg A. et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169–73.Foster K., Prowse A., van den Berg A. et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169–73.7.7. Gnarra J.R., Tory K., Weng Y. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85–90.Gnarra J.R., Tory K., Weng Y. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85–90.8.8. Shuin T., Kondo K., Torigoe S. et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852–5.Shuin T., Kondo K., Torigoe S. et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852–5.9.9. Kondo K., Yao M., Yoshida M. et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002;34:58–68.Kondo K., Yao M., Yoshida M. et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002;34:58–68.10.10. Nuan X., Rian C., Messing E.et al. Overproduction of vascular endkthelial growth factor related to VHL tumor supressor gene mutations and hypoxia-unducible factor-1a expression in renall cell carcinoma. J Urology 2003;170:588−92.Nuan X., Rian C., Messing E.et al. Overproduction of vascular endkthelial growth factor related to VHL tumor supressor gene mutations and hypoxia-unducible factor-1a expression in renall cell carcinoma. J Urology 2003;170:588−92.11.11. Yao M., Yoshida M., Kishida T. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569–75.Yao M., Yoshida M., Kishida T. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569–75.12.12. Patard J.J., Fergelot P., Karakiewicz P.I. et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008;123:395–400.Patard J.J., Fergelot P., Karakiewicz P.I. et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008;123:395–400.13.13. Smits K.M., Schouten L.J., van Dijk B.A. et al. Genetic and epigenetic alterations in the von hippel-lindau gene: the infl uence on renal cancer prognosis. Clin Cancer Res 2008;14:782–7.Smits K.M., Schouten L.J., van Dijk B.A. et al. Genetic and epigenetic alterations in the von hippel-lindau gene: the infl uence on renal cancer prognosis. Clin Cancer Res 2008;14:782–7.14.14. Schraml P., Struckmann K., Hatz F. et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002;196:186–93.Schraml P., Struckmann K., Hatz F. et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002;196:186–93.15.15. Rini B.I., Jaeger E., Weinberg V. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von HippelLindau gene status. BJU Int 2006;98:756–62.Rini B.I., Jaeger E., Weinberg V. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von HippelLindau gene status. BJU Int 2006;98:756–62.16.16. Choueiri T.K., Vaziri S.A., Jaeger E. et al. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860–5; discussion 865–6.Choueiri T.K., Vaziri S.A., Jaeger E. et al. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860–5; discussion 865–6.17.17. Klatte T., Seligson D.B., Riggs S.B. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007;13(24):7388–93.Klatte T., Seligson D.B., Riggs S.B. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007;13(24):7388–93.18.18. Birner P., Schindl M., Obermair A., Plank C. et al. Overexpression of hypoxiainducible factor 1a is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693– 6.Birner P., Schindl M., Obermair A., Plank C. et al. Overexpression of hypoxiainducible factor 1a is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693– 6.19.19. Schindl M., Schoppmann S.F., Samonigg H. et al. Overexpression of hypoxiainducible factor 1a is associated with an unfavourable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831–7.Schindl M., Schoppmann S.F., Samonigg H. et al. Overexpression of hypoxiainducible factor 1a is associated with an unfavourable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831–7.20.20. Miller K., Wang M., Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76.Miller K., Wang M., Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76.21.21. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metasta tic colorectal cancer. N Engl J Med 2004;350:2335–42.Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metasta tic colorectal cancer. N Engl J Med 2004;350:2335–42.22.22. Lovet J.M., Ricci S., Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.Lovet J.M., Ricci S., Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.